Repligen Eyes Acquisition of Maravai LifeSciences Holdings

Repligen, a drug manufacturing equipment provider, has proposed an acquisition of Maravai LifeSciences Holdings, a vaccine capping reagent vendor valued at $2.2 billion. The outcome is uncertain, and Repligen may divest some divisions if the deal proceeds. Maravai became a takeover target after losing 80% of its market value.

Repligen, a provider of drug manufacturing equipment, has made an acquisition offer to Maravai LifeSciences Holdings, a vendor of vaccine capping reagents with a market value of $2.2 billion, according to sources familiar with the matter.

The deal's outcome remains uncertain, and Repligen is considering the possibility of divesting some of Maravai's divisions if the acquisition is successful, one source indicated. Both companies have declined to comment on the matter.

Maravai has become an attractive takeover target, having lost nearly 80% of its value since peaking in August 2021, as it struggled to diversify beyond COVID-19 vaccine-related products.

(With inputs from agencies.)